NCT05823636

Brief Summary

Dyspepsia is one of the most common gastrointestinal diseases. This disease was defined as predominant epigastric pain lasting for at least 1 month, which can be accompanied with other symptoms, such as epigastric fullness, and early satiety. Despite dyspepsia symptoms lasting for ≥1 month represented clinical problem, a longer duration of 6 months or more after first-onset symptom was required for the diagnosis of functional dyspepsia based on ROME IV criteria. It was unclear about the natural procession of first-onset dyspepsia to functional dyspepsia assessed by Rome IV or Asia criteria and possible factors associated with this progression.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
220

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2023

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 26, 2023

Completed
26 days until next milestone

First Posted

Study publicly available on registry

April 21, 2023

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

September 26, 2024

Status Verified

September 1, 2024

Enrollment Period

2.5 years

First QC Date

March 26, 2023

Last Update Submit

September 24, 2024

Conditions

Keywords

Functional Dyspepsiauninvestigated dyspepsia

Outcome Measures

Primary Outcomes (1)

  • Functional dyspepsia defined by ROME IV criteria

    Met the following criteria: by one or more of the following symptoms: postprandial fullness, early satiation, epigastric pain, and epigastric burning that are unexplained after a routine clinical evaluation, Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis.

    6 months

Secondary Outcomes (8)

  • Functional dyspepsia defined by Asia criteria:

    3 month

  • Global Overall Symptom score (GOSS)

    1month, 3 months, 6 months

  • Number of participants subclassified into different subtypes of functional dyspepsia defined by ROME IV criteria

    6 months

  • Short Form of Nepean Dyspepsia Index (SF-NDI)

    1month, 3 months, 6 months

  • Hospital anxiety and depression scale

    1month, 3 months, 6 months

  • +3 more secondary outcomes

Study Arms (1)

uninvestigated dyspepsia

Patients aged ≥ 18 years old who had first-onset dyspepsia with one or more symptoms of epigastric pain, epigastric burning, postprandial fullness, early satiation and that has lasted for more than 1 month to 3 months.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients aged ≥ 18 years old who had first-onset dyspepsia with one or more symptoms of epigastric pain, epigastric burning, postprandial fullness, early satiation and that has lasted for more than 1 month to 3 months.

You may qualify if:

  • Patients aged ≥ 18 years old who had first-onset dyspepsia with one or more symptoms of epigastric pain, epigastric burning, postprandial fullness, early satiation and that has lasted for more than 1 month to 3 months.

You may not qualify if:

  • Patients with local or systemic diseases which may cause dyspeptic symptoms:
  • Known active peptic ulcer, cholecystitis, gallstone, gastrointestinal obstruction, gastroparesis, and etc.
  • Known acute or chronic injury of liver or kidney
  • Obvious hematological abnormality, or endocrine and metabolic diseases
  • Known malignancy; Obvious cardiovascular or cerebrovascular diseases (such as coronary heart disease, arrhythmia, cerebral infarction and etc.
  • Other conditions which may be associated with dyspeptic symptoms (such as NSAIDs associated dyspepsia)
  • organ failure defined by Marshall standard or severe psychiatric illnesses
  • pregnancy or lactation
  • unable to provide consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Air Force Military Medical University, China

Xi'an, Shaanxi, 710032, China

RECRUITING

MeSH Terms

Conditions

Dyspepsia

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Yanglin Pan, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor

Study Record Dates

First Submitted

March 26, 2023

First Posted

April 21, 2023

Study Start

January 1, 2023

Primary Completion

June 30, 2025

Study Completion

December 31, 2025

Last Updated

September 26, 2024

Record last verified: 2024-09

Locations